Evaluation of critical quality attributes of an anti-HER2 humanized monoclonal antibody drug

Xiao-Wen WANG.
Chinese Pharmaceutical Journal ; (24): 1054-1061, 2015.
Artículo en Zh | WPRIM | ID: wpr-859538

Documentos relacionados

  1. [Characterization of the size variants of a recombinant humanized monoclonal antibody (rhumAb1)].
  2. Physicochemical and Biological Characterization of RTXM83, a New Rituximab Biosimilar.
  3. Preparation and biological activities of anti-HER2 monoclonal antibodies with fully core-fucosylated homogeneous bi-antennary complex-type glycans.
  4. Macrophage N-glycan processing inhibits antibody-dependent cellular phagocytosis.
  5. Impact of mAb Aggregation on Its Biological Activity: Rituximab as a Case Study.
  6. Charge variants of proposed biosimilar to Omalizumab: Isolation, purification and analysis by HPLC methods.
  7. Drifts in N-Linked Glycosylation Result in ADCC Potency Variation of Perjeta® from August 2020 to October 2021 in China.
  8. Specific location of galactosylation in an afucosylated antiviral monoclonal antibody affects its FcγRIIIA binding affinity.
  9. Cadonilimab, a tetravalent PD-1/CTLA-4 bispecific antibody with trans-binding and enhanced target binding avidity.
  10. Robustness and repeatability of GlycoWorks RapiFluor-MS IgG N-glycan profiling in a long-term high-throughput glycomic study.